⚠️DEA Registration Revocation
The Drug Enforcement Administration's order revokes Massoud Amini, M.D.'s registration to handle controlled substances, citing the revocation of his California medical license. The decision underscores the necessity for practitioners to maintain state licensing to comply with federal regulations, affecting their ability to operate lawfully in the medical field.
Learn More⚖️DEA Notice
Catalent Greenville, Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
Learn More💼Aveva Drug Delivery Systems Seeks Importer Registration for Controlled Substances
Aveva Drug Delivery Systems, Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
Learn More📋DEA Notice
Vici Health Sciences, LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
Learn More💼Groff Health, Inc.'s DEA Registration Notice for Controlled Substances
Groff Health, Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
Learn More💊New DEA Regulations on Telemedicine and Special Registration
The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 (the "Ryan Haight Act") generally requires an in-person medical evaluation prior to the issuance of a prescription of controlled substances but provides an exception to this in-person medical evaluation requirement where the practitioner is engaged in the "practice of telemedicine" within the meaning of the Ryan Haight Act. These proposed regulatory changes would establish a Special Registration framework and authorize three types of Special Registration. This proposed rulemaking also provides for heightened prescription, recordkeeping, and reporting requirements. DEA believes such changes are necessary to effectively expand patient access to controlled substance medications via telemedicine while mitigating the risks of diversion associated with such expansion. A summary of this rule may be found at https://www.regulations.gov/docket/DEA-2023-0029.
Learn More